Imam Waked

11.0k total citations · 2 hit papers
134 papers, 3.5k citations indexed

About

Imam Waked is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Imam Waked has authored 134 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Hepatology, 104 papers in Epidemiology and 14 papers in Surgery. Recurrent topics in Imam Waked's work include Liver Disease Diagnosis and Treatment (93 papers), Hepatitis C virus research (79 papers) and Hepatitis B Virus Studies (59 papers). Imam Waked is often cited by papers focused on Liver Disease Diagnosis and Treatment (93 papers), Hepatitis C virus research (79 papers) and Hepatitis B Virus Studies (59 papers). Imam Waked collaborates with scholars based in Egypt, United States and United Kingdom. Imam Waked's co-authors include Asmaa Gomaa, Simon D. Taylor‐Robinson, Shahid A. Khan, Mireille B. Toledano, Gamal Esmat, Mohamed El‐Kassas, Wael Abdel‐Razek, Naglaa Allam, Ahmed Gomaa and Yasser Fouad and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Imam Waked

123 papers receiving 3.5k citations

Hit Papers

Hepatocellular carcinoma: Epidemiology, risk factors and ... 2008 2026 2014 2020 2008 2020 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis
    2008 548 citations Asmaa Gomaa, Imam Waked et al. profile →
  2. What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’
    2020 207 citations Yasser Fouad, Imam Waked et al. Liver International profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Imam Waked Egypt 29 2.4k 2.3k 555 376 267 134 3.5k
Zu‐Yau Lin Taiwan 37 3.0k 1.3× 2.8k 1.2× 538 1.0× 328 0.9× 351 1.3× 205 4.3k
Gamal Esmat Egypt 39 3.4k 1.4× 3.3k 1.4× 696 1.3× 516 1.4× 297 1.1× 288 5.6k
Yoshizumi Shintani Japan 25 2.5k 1.1× 2.6k 1.1× 762 1.4× 261 0.7× 218 0.8× 33 3.6k
Akihiro Tamori Japan 36 2.5k 1.1× 2.4k 1.0× 998 1.8× 535 1.4× 458 1.7× 234 4.6k
Takeya Tsutsumi Japan 33 2.7k 1.1× 2.9k 1.2× 1.1k 2.0× 283 0.8× 273 1.0× 94 4.3k
Chien‐Hung Chen Taiwan 41 4.2k 1.8× 4.4k 1.9× 532 1.0× 318 0.8× 488 1.8× 233 5.6k
Hajime Fujie Japan 26 3.0k 1.3× 3.0k 1.3× 891 1.6× 276 0.7× 182 0.7× 35 4.2k
Jee‐Fu Huang Taiwan 38 3.9k 1.7× 4.0k 1.7× 425 0.8× 263 0.7× 432 1.6× 290 5.4k
Olufunmilayo Lesi Nigeria 25 1.2k 0.5× 1.3k 0.6× 569 1.0× 473 1.3× 305 1.1× 65 2.7k
Gary P. Jeffrey Australia 32 2.3k 1.0× 2.5k 1.1× 415 0.7× 185 0.5× 638 2.4× 138 4.5k

Countries citing papers authored by Imam Waked

Since Specialization
Citations

This map shows the geographic impact of Imam Waked's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Imam Waked with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Imam Waked more than expected).

Fields of papers citing papers by Imam Waked

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Imam Waked. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Imam Waked. The network helps show where Imam Waked may publish in the future.

Co-authorship network of co-authors of Imam Waked

This figure shows the co-authorship network connecting the top 25 collaborators of Imam Waked. A scholar is included among the top collaborators of Imam Waked based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Imam Waked. Imam Waked is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
El‐Kassas, Mohamed, Khalid Alswat, Asma Labidi, et al.. (2025). Frailty and MASLD in the Arab region: An urgent call for regional clinical and public health strategies. Arab Journal of Gastroenterology. 26(4). 315–317.
2.
Abdelsameea, Eman, et al.. (2023). Outcome of direct-acting antiviral treatment in patients with hepatitis C virus/hepatitis B virus coinfection. SHILAP Revista de lepidopterología. 13(1).
3.
Ezzat, Sameera, Ivane Gamkrelidze, Asmaa Gomaa, et al.. (2023). Impacts of the Egyptian national screening and treatment programme for viral hepatitis C: A cost‐effectiveness model. Liver International. 43(7). 1417–1426. 6 indexed citations
4.
Waked, Imam, Kakil Ibrahim Rasul, Wael Abdel‐Razek, et al.. (2023). Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region. Liver International. 43(10). 2062–2077. 5 indexed citations
5.
Attia, Dina, Shereen Abdel Alem, Wafaa Elakel, et al.. (2022). Prevalence and clinical characteristics of patients with metabolic dysfunction‐associated fatty liver disease with hepatitis C virus infection—a population‐based study. Alimentary Pharmacology & Therapeutics. 56(11-12). 1581–1590. 13 indexed citations
6.
Shen, Eric Yi-Liang, Mark Thursz, Imam Waked, et al.. (2022). Optimized Systematic Review Tool: Application to Candidate Biomarkers for the Diagnosis of Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 31(7). 1261–1274. 1 indexed citations
7.
Hassany, Mohamed, Wafaa Elakel, Mohamed AbdAllah, et al.. (2022). Seroprevalence of HBV/HCV coinfection among patients with HCV screened during the national campaign for HCV eradication in Egypt. Arab Journal of Gastroenterology. 23(4). 259–262. 3 indexed citations
8.
El‐Kassas, Mohamed, Wafaa Elakel, Mohamed Alboraie, et al.. (2022). Egyptian revalidation of non-invasive parameters for predicting esophageal varices in cirrhotic patients: A retrospective study. Arab Journal of Gastroenterology. 23(2). 120–124.
9.
Abdelsameea, Eman, et al.. (2020). Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients. Expert Review of Anti-infective Therapy. 19(8). 1053–1059. 6 indexed citations
10.
Blach, Sarah, Loreta A. Kondili, Alessio Aghemo, et al.. (2020). Impact of COVID-19 on global HCV elimination efforts. Journal of Hepatology. 74(1). 31–36. 184 indexed citations
11.
Abdel‐Razek, Wael, Mohamed Hassany, Manal H. El‐Sayed, et al.. (2019). Hepatitis C Virus in Egypt: Interim Report From the World’s Largest National Program. Clinical Liver Disease. 14(6). 203–206. 18 indexed citations
12.
Waziry, Reem, Asmaa Gomaa, Imam Waked, & Gregory J. Dore. (2018). Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. Arab Journal of Gastroenterology. 19(1). 26–32. 8 indexed citations
13.
Azim, Hamdy A., Ashraf Omar, Mohamed Shaker, et al.. (2018). Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study). Journal of Hepatocellular Carcinoma. Volume 5. 109–119. 19 indexed citations
14.
Elbaz, Tamer, Magdy El‐Serafy, Wafaa Elakel, et al.. (2017). Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. Journal of Interferon & Cytokine Research. 37(8). 348–353. 4 indexed citations
15.
Alsebaey, Ayman, et al.. (2017). Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease. European Journal of Gastroenterology & Hepatology. 30(2). 207–211. 24 indexed citations
16.
17.
Estes, Chris, Wael Abdel‐Razek, Eman Abdelsameea, et al.. (2015). Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Alimentary Pharmacology & Therapeutics. 42(6). 696–706. 64 indexed citations
18.
Eltabbakh, Mohamed, et al.. (2014). Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. Medical Oncology. 32(1). 432–432. 19 indexed citations
19.
Badra, Gamal, et al.. (2006). Serum Islet Cell Autoantibodies During Interferon α Treatment in Patients With HCV‐Genotype 4 Chronic Hepatitis. Journal of Immunology Research. 13(1). 11–15. 2 indexed citations
20.
Waked, Imam, et al.. (1995). High prevalence of hepatitis C in Egyptian patients with chronic liver disease.. Gut. 37(1). 105–107. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zu‐Yau Lin Breakdown of academic impact, for papers by Gamal Esmat Breakdown of academic impact, for papers by Yoshizumi Shintani Breakdown of academic impact, for papers by Akihiro Tamori Breakdown of academic impact, for papers by Takeya Tsutsumi Breakdown of academic impact, for papers by Chien‐Hung Chen Breakdown of academic impact, for papers by Hajime Fujie Breakdown of academic impact, for papers by Jee‐Fu Huang Breakdown of academic impact, for papers by Olufunmilayo Lesi Breakdown of academic impact, for papers by Gary P. Jeffrey
Rankless by CCL
2026